In the latest episode of New Insight, Veeral Sheth, MD sat down with Cedric Francois, MD, PhD, co-founder and chief executive officer/president of Apellis Pharmaceuticals. The two experts discussed the company's landmark therapy, pegcetacoplan (SYFOVRE™), for geographic atrophy and the decades-long journey toward FDA approval. Sheth also asked about Francois' evolving role in the company and the interplay between being a scientist, clinician, and corporate executive. The experts also touched on how the GA treatment landscape might evolve over the next few years and what will shape the future of retina. 

Please direct any podcast-related inquiries to [email protected].